Avanos Medical, Inc. (NYSE: AVNS) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.50 | Insider Own | 5.27% | Shs Outstand | 46.85M | Perf Week | 0.08% |
| Market Cap | 1.17B | Forward P/E | 19.99 | EPS next Y | 1.25 | Insider Trans | 0.00% | Shs Float | 46.03M | Perf Month | 0.16% |
| Enterprise Value | 1.24B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 3.80% | Perf Quarter | 1.13% |
| Income | -70.13M | P/S | 1.64 | EPS this Y | 166.67% | Inst Trans | - | Short Ratio | 1.39 | Perf Half Y | 90.76% |
| Sales | 715.90M | P/B | 1.48 | EPS next Y | 25.00% | ROA | -6.61% | Short Interest | 1.75M | Perf YTD | 122.53% |
| Book/sh | - | P/C | 31.59 | EPS next 5Y | 25.00% | ROE | -8.91% | 52W High | 25.49 -1.96% | Perf Year | 106.36% |
| Cash/sh | - | P/FCF | 156.10 | EPS past 3/5Y | - | ROIC | -6.03% | 52W Low | 9.30 168.71% | Perf 3Y | -4.44% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 0.82% -0.39% | Gross Margin | 48.55% | Volatility | 0.07% 0.22% | Perf 5Y | -27.69% |
| Dividend TTM | - | EV/Sales | 1.74 | EPS Y/Y TTM | 82.42% | Oper. Margin | -7.92% | ATR (14) | 0.06 | Perf 10Y | -27.40% |
| Dividend Ex-Date | - | Quick Ratio | 1.40 | Sales Y/Y TTM | 4.07% | Profit Margin | -9.69% | RSI (14) | 62.10 | Recom | 3.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.48 | EPS Q/Q | -15.38% | SMA20 | 0.23% | Beta | 1.55 | Target Price | 23.00 |
| Payout | 0.00% | Debt/Eq | 0.18 | Sales Q/Q | 8.33% | SMA50 | 0.37% | Rel Volume | 1.89 | Prev Close | 24.98 |
| Employees | 2,287 | LT Debt/Eq | 0.14 | Earnings | Aug 10 | SMA200 | 47.72% | Avg Volume | 1.10M | Price | 24.99 |
| IPO Date | Oct 21, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 57.14% 7.18% | Net Debt/EBITDA | -3.37 | Volume | 2,075,760 | Change | 0.04% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-30-24 | Reiterated | Stifel Nicolaus | Hold | $28 → $20 |
| Jul-25-23 | Downgrade | Keybanc | Overweight → Sector Weight | |
| Jan-06-23 | Reiterated | Morgan Stanley | Underweight | $28 → $26 |
| Jul-18-22 | Reiterated | Stifel Nicolaus | Hold | $28 |
| Jul-15-22 | Reiterated | Morgan Stanley | Underweight | $33 → $28 |
| May-05-22 | Reiterated | Morgan Stanley | Underweight | $33 |
| Aug-04-21 | Downgrade | Stephens & Co. | Overweight → Equal Weight | |
| Apr-13-20 | Upgrade | Barclays | Underweight → Equal Weight | |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold | |
| Nov-07-19 | Downgrade | Stifel Nicolaus | Buy → Hold |
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 716 | 701 | 688 | 673 | 684 | 745 | 715 | 698 | 652 | |
| Cost of Goods Sold Incl. D&A | 369 | 352 | 307 | 294 | 290 | 365 | 324 | 295 | 261 | |
| Gross Profit | 347 | 349 | 381 | 380 | 394 | 380 | 391 | 402 | 391 | |
| Selling, General and Administrative Excl. Other | 290 | 218 | 315 | 288 | 323 | 261 | 285 | 370 | 314 | |
| Research and Development | 23 | 23 | 26 | 27 | 31 | 32 | 35 | 38 | 42 | |
| Other Operating Expense | 91 | 170 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | |
| Operating Income | -57 | -62 | 40 | 65 | 42 | 87 | 71 | -5 | 35 | |
| Interest Expense | 8 | 4 | 12 | 15 | 10 | 3 | 16 | 15 | 26 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | -1 | -431 | -58 | -5 | -76 | -116 | -44 | -27 | |
| Net Income Before Taxes | -68 | -66 | -403 | -8 | 27 | 7 | -60 | -64 | -18 | |
| Income Taxes | 2 | 2 | -17 | 2 | 5 | 1 | -33 | -18 | -10 | |
| Consolidated Net Income | -69 | -68 | -392 | -62 | 51 | 6 | -27 | -46 | 58 | |
| Net Income From Continuing Operations | -69 | -68 | -386 | -10 | 22 | 6 | -27 | -46 | -8 | |
| Net Income | -69 | -68 | -392 | -62 | 51 | 6 | -27 | -46 | 58 | |
| EPS (Recurring) | -1.50 | -1.46 | -8.53 | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | |
| EPS (Basic, Before Extraordinaries) | -1.50 | -1.46 | -8.53 | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | |
| EPS (Diluted) | -1.50 | -1.46 | -8.53 | -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | |
| EBITDA | -22 | -33 | -346 | 51 | 78 | 49 | -2 | -12 | 37 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | 25.29 | 266.69 | — | — | 36.71 | |
| Price To Sales Ratio | 1.61 | 0.74 | 1.06 | 1.57 | 1.86 | 2.23 | 3.08 | 2.32 | 3.23 | |
| Gross Margin | 48.46 | 49.79 | 55.38 | 56.46 | 57.60 | 51.01 | 54.69 | 57.59 | 59.97 | |
| Operating Margin | -7.96 | -8.84 | 5.81 | 9.66 | 6.14 | 11.68 | 9.93 | -0.72 | 5.37 | |
| Net Margin | -9.64 | -9.70 | -56.98 | -9.21 | 7.46 | 0.81 | -3.78 | -6.59 | 8.90 | |
| Shares Outstanding | 46 | 46 | 46 | 47 | 47 | 48 | 48 | 48 | 47 | |
| Market Capitalization | 1,150 | 517 | 732 | 1,054 | 1,272 | 1,664 | 2,202 | 1,618 | 2,105 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hurley John Joseph | Principal Accounting Officer | Mar 06 '26 | Option Exercise | 13.79 | 919 | 12,673 | 12,283 | Mar 10 |
| Galovan Scott Michael | SVP, Chief Financial Officer | Mar 06 '26 | Option Exercise | 13.79 | 5,907 | 81,458 | 116,916 | Mar 10 |
| Holbrook Kerr | SVP, Chief Commercial Officer | Nov 18 '25 | Sale | 11.00 | 15,000 | 165,015 | 83,860 | Nov 19 |
| BLACKFORD GARY | Director | Aug 13 '25 | Buy | 10.99 | 60,000 | 659,300 | 91,593 | Aug 15 |
| Holbrook Kerr | SVP, Chief Commercial Officer | Mar 06 '25 | Sale | 15.25 | 7,000 | 106,778 | 82,047 | Mar 10 |
| James Mojirade | SVP, General Counsel | Mar 04 '25 | Option Exercise | 0.00 | 8,039 | 0 | 78,352 | Mar 06 |
| Woody Joseph Fralin | other: Former Chief Executive Officer | Mar 04 '25 | Option Exercise | 0.00 | 32,158 | 0 | 453,203 | Mar 06 |
| Holbrook Kerr | SVP, Chief Commercial Officer | Mar 04 '25 | Option Exercise | 0.00 | 5,145 | 0 | 92,393 | Mar 06 |
| Hurley John Joseph | Principal Accounting Officer | Mar 04 '25 | Option Exercise | 0.00 | 107 | 0 | 10,172 | Mar 06 |
| Greiner Michael | Interim CEO | Mar 04 '25 | Option Exercise | 0.00 | 12,149 | 0 | 214,235 | Mar 06 |
| Greiner Michael | SVP - Chief Financial Officer | Mar 18 '24 | Option Exercise | 0.00 | 4,219 | 0 | 155,714 | Mar 19 |
| Holbrook Kerr | SVP, Chief Commercial Officer | Mar 18 '24 | Option Exercise | 0.00 | 2,531 | 0 | 89,727 | Mar 19 |
| Woody Joseph Fralin | Chief Executive Officer | Mar 18 '24 | Option Exercise | 0.00 | 15,821 | 0 | 453,810 | Mar 19 |
| Greiner Michael | SVP - Chief Financial Officer | Mar 14 '24 | Sale | 19.12 | 8,000 | 152,980 | 151,495 | Mar 15 |
| Shimer Julie Ann | Director | Mar 11 '24 | Buy | 19.85 | 500 | 9,925 | 50,090 | Mar 11 |